Packaging Development Jobs at Gracure Pharmaceutical Ltd | M.Pharm, B.Pharm can apply

Gracure Pharmaceutical Ltd. is a Delhi based pharmaceutical company, established in 1992 by Mr. A.S Bhargava with the vision of making world class affordable medicines. Gracure is a research driven forward looking pharmaceutical company with expertise in development of various finished dosage. Gracure R&D and EU-GMP approved Manufacturing Unit is located in Bhiwadi, Rajasthan.

Post : R&D – Packaging Development

Require Packaging Manager at Gracure Pharmaceutical Ltd | Only experience candidate

Gracure Pharmaceutical Ltd. is a Delhi based pharmaceutical company, established in 1992 by Mr. A.S Bhargava with the vision of making world class affordable medicines. Gracure is a research driven forward looking pharmaceutical company with expertise in development of various finished dosage. Gracure R&D and EU-GMP approved Manufacturing Unit is located in Bhiwadi, Rajasthan.

Post : Manager Packaging

Johnson & Johnson Pharmaceutical looking for Franchise Head – Reimburse Business | B.Pharm

Caring for the world, one person at a time has inspired and united the people of Johnson & Johnson for over 125 years. We embrace research and science -- bringing creative ideas, products, and services to advance the health and well-being of people. Every single day, our more than 130,000 employees across the world are blending heart, science, and ingenuity to profoundly change the trajectory of health for humanity.

Post : Associate Director - Reimbursed Business - Government Accounts

Video conference on Workplace Wellness for Better Immunity & Higher Productivity

PHD Chamber of Commerce and Industry, established in 1905, is a proactive National Apex Chamber working at the grass-root level and with strong national and international linkages.The Chamber acts as a catalyst in the promotion of industry, trade and entrepreneurship. PHD Chamber, through its research-based policy advocacy role, positively impacts the economic growth and development of the nation.PHD Chamber is more than an organisation of the business community, as it lives by the chosen motto In Communitys Life & Part of It and contributes significantly to socio-economic development and capacity building in several fields.

Novartis announced updated results from the landmark COMBI-AD clinical trial, demonstrating that treatment with Tafinlar® (dabrafenib) and Mekinist® (trametinib) following the surgical removal of melanoma offers a long-term and durable relapse-free survival (RFS) benefit to high-risk patients diagnosed with stage III, BRAF-mutation positive melanoma1. Researchers reported that 52% (95% CI, 48%-58%) of patients treated with adjuvant Tafinlar + Mekinist were alive and relapse-free at five years.

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies announced a clinical strategy to treat patients with moderate to severe COVID-19 who require hospitalization. ATR-002, an oral small molecule, has been proven in preclinical trials to block viral propagation of SARS-CoV-2 and to have an immunomodulatory effect leading to a decreased cytokine and chemokine release. This dual benefit makes the MEK-inhibitor ATR-002 particularly relevant for the treatment of COVID-19.